BR112016003868A8 - Método, aparelho, mídia de armazenamento não transitório, e, programa de computador - Google Patents

Método, aparelho, mídia de armazenamento não transitório, e, programa de computador

Info

Publication number
BR112016003868A8
BR112016003868A8 BR112016003868A BR112016003868A BR112016003868A8 BR 112016003868 A8 BR112016003868 A8 BR 112016003868A8 BR 112016003868 A BR112016003868 A BR 112016003868A BR 112016003868 A BR112016003868 A BR 112016003868A BR 112016003868 A8 BR112016003868 A8 BR 112016003868A8
Authority
BR
Brazil
Prior art keywords
computer program
perform
trainer
storage media
tissue
Prior art date
Application number
BR112016003868A
Other languages
English (en)
Other versions
BR112016003868A2 (pt
Inventor
Jan Van Ooijen Hendrik
Franciscus Johannes Verhaegh Wilhelmus
Van De Stolpe Anja
Original Assignee
Koninklijke Philips Nv
Innosign B V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Koninklijke Philips Nv, Innosign B V filed Critical Koninklijke Philips Nv
Publication of BR112016003868A2 publication Critical patent/BR112016003868A2/pt
Publication of BR112016003868A8 publication Critical patent/BR112016003868A8/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • GPHYSICS
    • G16INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16BBIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • GPHYSICS
    • G16INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16BBIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G16B25/10Gene or protein expression profiling; Expression-ratio estimation or normalisation
    • GPHYSICS
    • G16INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16CCOMPUTATIONAL CHEMISTRY; CHEMOINFORMATICS; COMPUTATIONAL MATERIALS SCIENCE
    • G16C99/00Subject matter not provided for in other groups of this subclass
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/106Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Theoretical Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Evolutionary Biology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Medical Informatics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Computing Systems (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Algebra (AREA)
  • General Physics & Mathematics (AREA)
  • Mathematical Analysis (AREA)
  • Mathematical Optimization (AREA)
  • Mathematical Physics (AREA)
  • Pure & Applied Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

MÉTODO, APARELHO, MÍDIA DE ARMAZENAMENTO NÃO TRANSITÓRIO, E, PROGRAMA DE COMPUTADOR. A presente invenção refere-se a um método que compreende inferir a atividade de uma via de sinalização celular PI3K em um tecido e/ou em células e/ou em um fluido corpóreo de um paciente, com base ao menos nos níveis de expressão de um ou mais genes-alvo da via de sinalização celular PI3K medidos em uma amostra extraída do tecido e/ou das células e/ou do fluido corpóreo do paciente. A presente invenção refere-se, adicionalmente, a um aparelho que compreende um processador digital configurado para executar esse tipo de método, a uma mídia de armazenamento não transitório que armazena instruções que são executáveis por um dispositivo de processamento digital para executar esse tipo de método, e a um programa de computador que compreende meios de código de programa para fazer com que um dispositivo de processamento digital execute esse tipo de método.
BR112016003868A 2014-01-03 2014-12-30 Método, aparelho, mídia de armazenamento não transitório, e, programa de computador BR112016003868A8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14150145 2014-01-03
PCT/EP2014/079468 WO2015101635A1 (en) 2014-01-03 2014-12-30 Assessment of the pi3k cellular signaling pathway activity using mathematical modelling of target gene expression.

Publications (2)

Publication Number Publication Date
BR112016003868A2 BR112016003868A2 (pt) 2017-12-05
BR112016003868A8 true BR112016003868A8 (pt) 2022-11-08

Family

ID=49920140

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016003868A BR112016003868A8 (pt) 2014-01-03 2014-12-30 Método, aparelho, mídia de armazenamento não transitório, e, programa de computador

Country Status (10)

Country Link
US (2) US11261495B2 (pt)
EP (1) EP3013986B1 (pt)
JP (1) JP6077178B2 (pt)
CN (2) CN112795650A (pt)
AU (1) AU2014375206B2 (pt)
BR (1) BR112016003868A8 (pt)
CA (1) CA2923092C (pt)
DK (1) DK3013986T3 (pt)
ES (1) ES2613521T3 (pt)
WO (1) WO2015101635A1 (pt)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2015334841B2 (en) 2014-10-24 2022-02-03 Koninklijke Philips N.V. Medical prognosis and prediction of treatment response using multiple cellular signaling pathway activities
CA2965408C (en) 2014-10-24 2023-10-24 Koninklijke Philips N.V. Medical prognosis and prediction of treatment response using multiple cellular signaling pathway activities
US10016159B2 (en) 2014-10-24 2018-07-10 Koninklijke Philips N.V. Determination of TGF-β pathway activity using unique combination of target genes
BR112018002848A2 (pt) 2015-08-14 2018-11-06 Koninklijke Philips Nv método, aparelho, mídia de armazenamento não transitório, programa de computador, kit para medir níveis de expressão de seis ou mais genes-alvo da via de sinalização celular
RU2019100441A (ru) * 2016-06-13 2020-07-14 Конинклейке Филипс Н.В. Способ логического вывода об активности транскрипционного фактора пути сигнальной трансдукции у субъекта
CN110382521B (zh) * 2016-11-25 2024-07-05 皇家飞利浦有限公司 从氧化应激区分肿瘤抑制性foxo活性的方法
EP3431582A1 (en) 2017-07-18 2019-01-23 Koninklijke Philips N.V. Cell culturing materials
EP3462348A1 (en) 2017-09-28 2019-04-03 Koninklijke Philips N.V. Bayesian inference
CA3077501A1 (en) * 2017-10-02 2019-04-11 Koninklijke Philips N.V. Determining functional status of immune cells types and immune response
EP3461915A1 (en) * 2017-10-02 2019-04-03 Koninklijke Philips N.V. Assessment of jak-stat1/2 cellular signaling pathway activity using mathematical modelling of target gene expression
EP3502279A1 (en) * 2017-12-20 2019-06-26 Koninklijke Philips N.V. Assessment of mapk-ap 1 cellular signaling pathway activity using mathematical modelling of target gene expression
JP7406213B2 (ja) * 2018-01-24 2023-12-27 トーマス・ジェファーソン・ユニバーシティ バイオ拡散チャンバおよびその製造方法
EP3812474A1 (en) 2019-10-22 2021-04-28 Koninklijke Philips N.V. Methods of prognosis in high-grade serous ovarian cancer
JP7386897B2 (ja) * 2019-05-03 2023-11-27 コーニンクレッカ フィリップス エヌ ヴェ 高悪性度漿液性卵巣癌における予後予測の方法
EP3739588A1 (en) 2019-05-13 2020-11-18 Koninklijke Philips N.V. Assessment of multiple signaling pathway activity score in airway epithelial cells to predict airway epithelial abnormality and airway cancer risk
EP3882363A1 (en) 2020-03-17 2021-09-22 Koninklijke Philips N.V. Prognostic pathways for high risk sepsis patients
EP3978628A1 (en) 2020-10-01 2022-04-06 Koninklijke Philips N.V. Prognostic pathways for viral infections
WO2021209567A1 (en) 2020-04-16 2021-10-21 Koninklijke Philips N.V. Prognostic pathways for viral infections
EP3940704A1 (en) 2020-07-14 2022-01-19 Koninklijke Philips N.V. Method for determining the differentiation state of a stem cell
EP3960875A1 (en) 2020-08-28 2022-03-02 Koninklijke Philips N.V. Pcr method and kit for determining pathway activity
EP3965119A1 (en) 2020-09-04 2022-03-09 Koninklijke Philips N.V. Methods for estimating heterogeneity of a tumour based on values for two or more genome mutation and/or gene expression related parameter, as well as corresponding devices
EP3974540A1 (en) 2020-09-25 2022-03-30 Koninklijke Philips N.V. Method for predicting immunotherapy resistance
EP4015651A1 (en) 2020-12-17 2022-06-22 Koninklijke Philips N.V. Treatment prediction and effectiveness of anti-tnf alpha treatment in ibd patients
EP4039825A1 (en) 2021-02-09 2022-08-10 Koninklijke Philips N.V. Comparison and standardization of cell and tissue culture
WO2022189530A1 (en) 2021-03-11 2022-09-15 Koninklijke Philips N.V. Prognostic pathways for high risk sepsis patients

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1592791A2 (en) * 2003-02-10 2005-11-09 National Institute of Advanced Industrial Science and Technology Regulation of gene expression by dna interference
RU2010111116A (ru) * 2007-08-24 2011-09-27 Онкотерапи Сайенс, Инк. (Jp) Pkib и naaladl2 в качестве генов-мишеней в терапии и диагностике рака предстательной железы
KR20110052627A (ko) * 2008-07-16 2011-05-18 다나-파버 캔서 인스티튜트 인크. 전립선암과 관련된 시그너처 및 pc결정인자 및 그의 사용 방법
MX2012011887A (es) * 2010-04-16 2012-11-30 Genentech Inc Foxo 3a como biomarcador predictivo para la eficacia del inhibidor de la via de quinasa pi3k/akt.
EP2549399A1 (en) 2011-07-19 2013-01-23 Koninklijke Philips Electronics N.V. Assessment of Wnt pathway activity using probabilistic modeling of target gene expression
JP6449779B2 (ja) 2012-12-26 2019-01-09 コーニンクレッカ フィリップス エヌ ヴェKoninklijke Philips N.V. 目的遺伝子発現の線形結合を用いた細胞信号伝達経路活性の評価
US11309059B2 (en) 2013-04-26 2022-04-19 Koninklijke Philips N.V. Medical prognosis and prediction of treatment response using multiple cellular signalling pathway activities
EP3461916A1 (en) * 2017-10-02 2019-04-03 Koninklijke Philips N.V. Assessment of jak-stat3 cellular signaling pathway activity using mathematical modelling of target gene expression

Also Published As

Publication number Publication date
JP6077178B2 (ja) 2017-02-08
US11261495B2 (en) 2022-03-01
AU2014375206B2 (en) 2021-09-30
BR112016003868A2 (pt) 2017-12-05
ES2613521T3 (es) 2017-05-24
EP3013986B1 (en) 2016-11-16
CN112795650A (zh) 2021-05-14
US20220259666A1 (en) 2022-08-18
JP2016536976A (ja) 2016-12-01
WO2015101635A1 (en) 2015-07-09
AU2014375206A1 (en) 2016-03-03
CN105492630A (zh) 2016-04-13
US20160298196A1 (en) 2016-10-13
CA2923092A1 (en) 2015-07-09
CA2923092C (en) 2019-12-17
EP3013986A1 (en) 2016-05-04
DK3013986T3 (en) 2017-02-27

Similar Documents

Publication Publication Date Title
BR112016003868A8 (pt) Método, aparelho, mídia de armazenamento não transitório, e, programa de computador
BR112015015131A2 (pt) método, aparelho, mídia de armazenamento não transitório, programa de computador, e produto
BR112018002848A2 (pt) método, aparelho, mídia de armazenamento não transitório, programa de computador, kit para medir níveis de expressão de seis ou mais genes-alvo da via de sinalização celular
BR112014000965B8 (pt) Método, aparelho e meio de armazenamento não transitório
BR112018008357A2 (pt) mutações de ponto em câncer resistente a inibidor de trk e métodos relacionados às mesmas
BR112019022538A8 (pt) Técnicas para pareamento comportamental em um sistema de centro de contato
BR112017026709A2 (pt) tratamento e diagnóstico de câncer
BR112017025045A2 (pt) plx-8394 ou plx-7904 para uso no tratamento de doenças relacionadas a braf-v600
GB2552267A (en) Detection and treatment of disease exhibiting disease cell heterogeneity and systems and methods for communicating test results
BR112016016658A2 (pt) proteína de fusão de um anticorpo, polinucleotídeo, vetor, célula hospedeira, composição farmacêutica, métodos para produzir uma proteína de fusão e de tratamento de uma doença em um indivíduo e uso da proteína de fusão
BR112019010553A2 (pt) método para inferir a atividade de uma via de sinalização celular pi3k em um indivíduo e programa de computador
BR112016020897A2 (pt) ?determinação da agressividade de câncer, prognóstico e capacidade de reação a tratamento?
BR112014026648A8 (pt) método implementado por um dispositivo de computação e aparelho para determinar uma porção futura de um programa de mídia
WO2017116817A3 (en) Testing of medicinal drugs and drug combinations
CY1123793T1 (el) Γονιδιακη θεραπεια rpgr για μελαγχρωστικη αμφιβληστροειδοπαθεια
WO2014124339A3 (en) Use of translational profiling to identify target molecules for therapeutic treatment
BR112018003238A2 (pt) seleção de pacientes para terapia de combinação
EA201790211A1 (ru) Способ прогнозирования результата лечения афлиберцептом пациента, предположительно страдающего от рака
BR112017014361A2 (pt) métodos para aperfeiçoamento de terapia celular
BR112015030526A2 (pt) detecção de aorta automatizada em um volume de tca
BR112016024143A2 (pt) tratamento de câncer
BR112015017903A2 (pt) vacina de subunidade de mycobacterium avium subsp. paratuberculosis única ou de múltiplos estágios
MX2020006388A (es) Biomarcadores para el diagnostico y pronostico de trastornos ectaticos de la cornea.
MX2017006959A (es) Metodos para establecer un regimen de dosificacion de vedolizumab para tratar pacientes con enfermedad del intestino irritable.
BR112017008805A2 (pt) tratamento de córnea usando laminina

Legal Events

Date Code Title Description
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B25A Requested transfer of rights approved

Owner name: INNOSIGN B.V. (NL)

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.